ABBOTT LABORATORIES — Director's Dealing 2016

Feb 24, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2016-02-19

Reporting Person: FREYMAN THOMAS C (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-19	Common shares without par value	A	55338	—	Acquired	402590	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-19	Option (right to buy)	$38.40	A	485159	Acquired	2026-02-18	Common shares (485159)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	1123	Indirect
Common shares without par value	4000	Indirect
Common shares without par value	76000	Indirect
Common shares without par value	76000	Indirect
Common shares without par value	1941	Indirect
Common shares without par value	1941	Indirect

Footnotes

F1: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 19, 2016.

F3: Held in the Annette Newton-Freyman 1994 Trust. The reporting person's spouse is trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.

F4: Held in the Annette Newton-Freyman 2012 Irrevocable Trust. The reporting person is trustee of the trust. The trust is irrevocable. The reporting person disclaims beneficial ownership of these securities.

F5: Held in the Thomas C. Freyman 2012 Irrevocable Trust. The reporting person's spouse is trustee of the trust. The trust is irrevocable.

F6: The reporting person disclaims beneficial ownership of all securities held by his son.

F7: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 161,720 on 02/19/2017, 161,719 on 02/19/2018, and 161,720 on 02/19/2019.